Healthcare Analytical Testing Services Market

Healthcare Analytical Testing Services Market by Type (Method Development & Validation, Cell-based Assays, Stability Testing, Heavy Metal Testing, Thermal Analysis, Cleaning Validation), End User (Pharmaceutical Companies, CROs) - Global Forecast to 2026

Report Code: AST 4341 Sep, 2021, by marketsandmarkets.com

[357 Pages Report] The healthcare analytical testing services market is projected to reach USD 9.8 billion by 2026 from USD 5.6 billion in 2021, at a CAGR of 11.9%. The shift in focus towards the analytical testing of biologics and biosimilars, increasing outsourcing of analytical testing by pharmaceutical companies and medical device companies, an increasing number of clinical trials, and the rising acceptance of the QbD approach in pharma research and manufacturing are the major factors driving the growth of the healthcare analytical testing services market.

Healthcare Analytical Testing Services Market

To know about the assumptions considered for the study, Request for Free Sample Report

COVID-19 Impact on the Healthcare analytical testing services Market

To assess the impact of COVID-19 and provide market forecasts, scenario-based approaches are considered.

In the optimistic scenario, the COVID-19 pandemic would have a significant positive long-term impact on the healthcare analytical testing services market. Initially, because of lockdowns and quarantine measures, the growth of this market was hampered, especially due to delays in starting new clinical trials and suspended enrolment in most ongoing clinical studies by leading players in the pharmaceutical industry. However, the overwhelming global demand for COVID-19 testing, treatment, and vaccine development has driven the growth of the healthcare analytical testing services market due to the simultaneous increase in demand and requirement for bioanalytical testing, method development, and validation, as well as safety testing of potential treatments and vaccines.

There has also been a steady rise in investment in the pharmaceutical industry and many opportunities arising from new technologies and advances concerning the COVID-19 pandemic. The global health crisis triggered by the COVID-19 pandemic has made it imperative for the pharmaceutical industry to move rapidly alongside researchers, regulators, and CROs to develop diagnostics, treatment, and vaccines. Healthcare analytical testing services play an important role in this scenario to maintain quality, safety, and efficacy.

In a pessimistic scenario, it could be assumed that the COVID-19 pandemic has resulted only in a temporarily positive impact on the healthcare analytical testing services market. In this scenario, it may be assumed that there would be a significant reduction in new offerings and customer outsourcing trends in the post-pandemic period, which could affect the growth of the healthcare analytical testing service market in the coming years. Moreover, the efficacy of current vaccines against new variants of the coronavirus is unknown. This could indicate future lockdown and other virus containment measures that would negatively affect the healthcare analytical testing services market.

In a realistic scenario, it could be assumed that the effect of COVID-19 on the healthcare analytical testing services market has been positive and possibly long-term. In this scenario, the markedly positive impact on the healthcare analytical testing services market due to COVID-19 related vaccine and drug development in 2020 and 2021 would subside slowly in the coming years. Thereafter, the market growth is likely to stabilize and grow steadily, similar to the pre-pandemic scenario.

Healthcare analytical testing services Market Dynamics

Driver: Increasing outsourcing of analytical testing by pharmaceutical companies and medical device companies

Outsourcing analytical testing helps pharmaceutical companies mitigate risks by avoiding large investments in purchasing analytical equipment and maintaining manpower, especially when development efforts are in the early stages. The availability of specialized analytical testing service providers with key capabilities to provide optimum results rapidly has led to increasing consideration among pharmaceutical companies to outsource testing services to third-party service providers.

Medical device testing is also increasingly being outsourced by companies due to challenges faced by manufacturers to bring these devices to the market. There is a rising requirement to streamline medical device testing, ease internal resources and ensure necessary expertise and process credibility. This has led to productive partnerships between medical device manufacturers and healthcare analytical testing services companies, especially in the face of a changing regulatory landscape and disruptions caused by the current pandemic scenario.

Restraint: Shortage of skilled professionals

Healthcare analytical testing service providers face challenges in attracting and retaining highly skilled professionals. These companies compete with pharmaceutical, biotechnology, medical device, contract research companies, and academic and research institutions for qualified and experienced scientists. To compete effectively, companies are required to offer higher compensation and other benefits, which may affect the financial condition and results of operations, especially for small-scale analytical testing providers.

Another factor responsible for the dearth of skilled professionals in this field is the growth of the pharma industry towards novel molecular constructs and modes of action. This requires that staff be continually trained, with healthcare analytical testing companies working together with pharmaceutical companies and CROs to develop suitable industry training programs.

Opportunity: Emerging markets

Emerging markets present significant growth opportunities for providers of healthcare analytical testing services—particularly India and China. Governments in both countries are extensively emphasizing the development of life science infrastructure by undertaking several projects and initiatives to encourage pharma and biopharma companies to develop and manufacture drugs for various infectious and chronic diseases.

Challenge: Specific requirements of innovative formulations and medical devices

The diversity of CMC requirements for biopharmaceutical IND and the development of novel drug delivery systems pose various challenges and require various analytical methods for testing new drug molecules. Moreover, innovative medical devices such as disposable inhalation devices and non-invasive glucometers require unique analytical testing to comply with the regulatory requirements of the FDA and EMA. Thus, rapidly changing testing requirements form a key challenge faced by analytical testing service providers globally.

Moreover, smaller and larger pharmaceutical companies have different requirements from bioanalytical outsourcing. Smaller pharma companies rely on healthcare analytical testing companies for all aspects of method development, validation, and study support. This indicates that these companies require support for a large portion of their early-phase discovery studies. These projects are often critical for project progression with more aggressive timelines for the delivery of analytical data. These factors increase the pressure on healthcare analytical testing companies to cater to a greater variety of needs to suit their customers, thereby posing a challenge to the growth of the overall market.

The bioanalytical testing services segment holds the highest market share, by type,  in the Healthcare analytical testing services market

Based on type, bioanalytical testing, physical characterization, method development & validation, stability testing, batch-release testing, raw material testing, microbial testing, and environmental monitoring services. In 2020, the bioanalytical testing services segment accounted for the largest share of the market. The large share of this segment can be attributed to their utility in controlling the cost of drug development by effectively evaluating the therapeutic entity throughout the drug development cycle. The time constraints and the exorbitant costs of drug discovery and development in biopharmaceutical research are driving the market for bioanalytical testing services.

The batch-release testing segment is projected to grow at the highest CAGR in the healthcare analytical testing services market, by type, in the forecast period.

Based on type, bioanalytical testing, physical characterization, method development & validation, stability testing, batch-release testing, raw material testing, microbial testing, and environmental monitoring services.  Batch-release testing segment is growing at the highest CAGR, by type, in the by type segment. The high growth of this segment can be attributed to the to utility of these services in ensuring the quality of pharmaceuticals and biopharmaceuticals before release for sale, supply, or export.

The pharmaceutical & biopharmaceutical companies to hold the highest market share, by end user, in the forecast period

Based on the end user, the healthcare analytical testing services market has been segmented into pharmaceutical & biopharmaceutical companies, medical device companies, and contract research organizations (CROs). The large share of this segment is attributed to the increasing outsourcing of analytical testing services by these companies to boost profit margins, avoid high capital expenditure, and focus on their core business competencies.

North America holds the largest share in the Healthcare analytical testing services market, by region, in the forecast period

The Healthcare analytical testing services market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East & Africa. North America accounted for the largest share in the Healthcare analytical testing services market in 2020. The large share of this regional segment can be attributed to The large share of this region can primarily be attributed to the presence of a well-established base of pharmaceutical and biopharmaceutical companies, high investments in biosimilars & biologics segment, and increasing R&D expenditure.

Healthcare Analytical Testing Services Market  by Region

Key Market Players

Key players in the Healthcare analytical testing services market include Eurofins Scientific (Luxembourg), Laboratory Corporation of America Holdings (US), SGS S.A. (Switzerland), Charles River Laboratories (US), WuXi AppTec Co. Ltd. (China), PPD, Inc. (US), Element Materials Technology (UK), Thermo Fisher Scientific (US), Pace Analytical Services, LLC. (US), Intertek Group LLC. (UK), Merck KGaA (Germany), Danaher Corporation (US), Source BioScience (UK), Almac Group (UK), ICON plc (Ireland), Frontage Laboratories, Inc. (US), STERIS plc (US), Sartorius AG (Germany), ALS Life Science (US), Syneos Health (US), Medpace Holdings, Inc. (US), Cinven (LGC Limited) (UK), Anacura (Belgium), Impact Analytical (US), & CD BioSciences (US).

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market Size available for years

2019-2026

Base Year Considered

2020

Forecast period

2021-2026

Forecast Unit

Value(USD)

Segments covered

Healthcare analytical testing services Market:
By Type, By End User
 

Geographies covered

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Switzerland
    • Spain
    • Rest of Europe(RoE)
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia Pacific (RoAPAC)
  • Latin America
  • Middle East & Africa

Companies Covered

Eurofins Scientific (Luxembourg), Laboratory Corporation of America Holdings (US), SGS S.A. (Switzerland), Charles River Laboratories (US), WuXi AppTec Co. Ltd. (China), PPD, Inc. (US), Element Materials Technology (UK), Thermo Fisher Scientific (US), Pace Analytical Services, LLC. (US), Intertek Group LLC. (UK), Merck KGaA (Germany), Danaher Corporation (US), Source BioScience (UK), Almac Group (UK), ICON plc (Ireland), Frontage Laboratories, Inc. (US), STERIS plc (US), Sartorius AG (Germany), ALS Life Science (US), Syneos Health (US), Medpace Holdings, Inc. (US), Cinven (LGC Limited) (UK), Anacura (Belgium), Impact Analytical (US), & CD BioSciences (US).

The research report categorizes the market into the following segments and subsegments:

By Type

  • Bioanalytical Testing Services
    • Cell-Based Assay Services
    • Virology Testing Services
    • Immunogenicity & Neutralizing Antibody Testing Services
    • Biomarker Testing Services
    • Pharmacokinetic Testing Services
    • Other Bioanalytical Testing Services
  • Physical Characterization Services
    • Laser Particle Size Analysis  Services
    • Thermal Analysis Services
    • Image Analysis Services
    • Surface Area Analysis Services
    • Other Physical Characterization Services
  • Method Development & Validation Testing Services
    • Extractables & Leachables Method Development & Validation Services
    • Process Impurity Method Development & Validation Services
    • Stability-Indicating Method Validation Services
    • Cleaning Validation Method Development  Services
    • Analytical Standard Characterization Services
    • Technical Consulting Services
    • Other Method Validation Services
  • Raw Material Testing Services
    • Complete Compendial Testing Services
    • Heavy Metal Testing Services
    • Container Testing Services 
    • Karl Fischer Analysis Services
    • Wet Chemistry Analysis Services
    • Other Raw Material Testing Services
  • Batch-Release Testing Services
    • Dissolution Testing Services
    • Elemental Impurity Testing Services
    • Disintegration Testing Services
    • Hardness Testing Services
    • Friability Testing Services
    • Other Batch-Release Testing Services
  • Stability Testing
    • Drug Substance Stability Testing Services
    • Formulation Evaluation Stability Testing Services
    • Accelerated Stability Testing Services
    • Photostability Testing Services
    • Comparative Stability Testing Services
    • Other Stability Testing Services
  • Microbial Testing Services
    • Microbial Limit Testing Services
    • Sterility Testing Services
    • Endotoxin Testing Services
    • Preservative Efficacy Testing Services
    • Water Testing Services
    • Other Microbial Testing Services
  • Environmental Monitoring Services
    • Air Testing  Services
    • Wastewater/ETP Testing Services;
    • Other Environmental Monitoring Services

By End User

  • Pharmaceutical & Biopharmaceutical Companies
  • Medical Device Companies
  • Clinical Research Organizations

By Country/Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Switzerland
    • Rest Of Europe (RoE)
  • Asia Pacific (APAC)
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest Of APAC
  • Latin America
  • Middle East and Africa

Recent Developments:

  • In August 2021, WuXi AppTec (China) acquired a drug product manufacturing facility in Couvet, Switzerland, from Bristol Myers Squibb.
  • In June 2021, WuXi AppTec (China)  announced that WuXi STA would open a new pharmaceutical manufacturing campus in Delaware, US.
  •  In April 2021, SGS S.A. (Switzerland) acquired SYNLABS Analytics & Services (Germany) to strengthen SGS’ presence in Northwestern Europe, especially in Germany, Benelux, and the Nordic countries.
  • In April 2021, Charles River Laboratories (US) acquired Retrogenix Ltd. (UK), which provides air sampling and quality and offers cell microarray services, to boost its early-stage contract research organization offerings.
  • In May 2020, The Covance Drug Development business of Laboratory Corporation of America Holdings (US)  expanded its technology ecosystem to accelerate the adoption of decentralized clinical trials.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 45)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
                    FIGURE 1 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET SEGMENTATION 
                    FIGURE 2 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY REGION 
           1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 50)
    2.1 RESEARCH DATA
           FIGURE 3 RESEARCH DESIGN 
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 SECONDARY RESEARCH
           2.1.3 PRIMARY DATA
                    FIGURE 4 PRIMARY SOURCES 
                    2.1.3.1 Key data from primary sources
                    2.1.3.2 Insights from primary experts
                               FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 
                               FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY, DESIGNATION, AND REGION 
    2.2 MARKET SIZE ESTIMATION: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET
           FIGURE 7 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 
           FIGURE 8 REVENUE SHARE ANALYSIS ILLUSTRATION 
           FIGURE 9 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE HEALTHCARE ANALYTICAL TESTING SERVICES MARKET (2021–2026) 
           FIGURE 10 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 
           FIGURE 11 TOP-DOWN APPROACH 
    2.3 MARKET BREAKDOWN & DATA TRIANGULATION
           FIGURE 12 DATA TRIANGULATION METHODOLOGY 
    2.4 MARKET SHARE ESTIMATION
    2.5 ASSUMPTIONS FOR THE STUDY
    2.6 LIMITATIONS
           2.6.1 METHODOLOGY-RELATED LIMITATIONS
           2.6.2 SCOPE-RELATED LIMITATIONS
    2.7 RISK ASSESSMENT
           TABLE 1 RISK ASSESSMENT: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET

3 EXECUTIVE SUMMARY (Page No. - 62)
    FIGURE 13 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
    FIGURE 14 BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
    FIGURE 15 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
    FIGURE 16 GEOGRAPHIC SNAPSHOT OF THE HEALTHCARE ANALYTICAL TESTING SERVICES MARKET

4 PREMIUM INSIGHTS (Page No. - 65)
    4.1 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET OVERVIEW
           FIGURE 17 GROWTH IN THE MARKET DRIVEN BY THE GROWING DEVELOPMENT OF PHARMACEUTICALS
    4.2 NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE
           FIGURE 18 BIOANALYTICAL TESTING SERVICES COMMANDED THE LARGEST SHARE IN THE HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, IN 2020
    4.3 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: GEOGRAPHIC MIX
           FIGURE 19 CHINA TO WITNESS THE HIGHEST GROWTH IN THE HEALTHCARE ANALYTICAL TESTING SERVICES MARKET DURING THE FORECAST PERIOD
    4.4 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: REGIONAL MIX (2020–2025)
           FIGURE 20 NORTH AMERICA TO DOMINATE THE MARKET IN THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 69)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 21 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Focus on analytical testing of biologics & biosimilars
                               TABLE 2 PATENT EXPIRY OF BEST-SELLING BIOLOGICS
                    5.2.1.2 Increasing outsourcing of analytical testing by pharmaceutical companies and medical device companies
                    5.2.1.3 Increasing number of clinical trials
                               FIGURE 22 INCREASING NUMBER OF CLINICAL TRIALS WORLDWIDE (2002–2021)
                    5.2.1.4 Rising acceptance of the quality-by-design approach in pharma research and manufacturing
           5.2.2 RESTRAINTS
                    5.2.2.1 Shortage of skilled professionals
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Specialized testing
                    5.2.3.2 Emerging markets
           5.2.4 CHALLENGES
                    5.2.4.1 Specific requirements of innovative formulations and medical devices
                    5.2.4.2 Need to improve the sensitivity of bioanalytical methods
                    5.2.4.3 Rising costs of bioanalytical testing methods and technology
    5.3 COVID-19 IMPACT ANALYSIS
           5.3.1 COVID-19 HEALTH ASSESSMENT
    5.4 COVID-19 ECONOMIC ASSESSMENT
    5.5 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
           FIGURE 23 CRITERIA IMPACTING THE GLOBAL ECONOMY
    5.6 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE HEALTHCARE ANALYTICAL TESTING SERVICES MARKET
           THE HEALTHCARE ANALYTICAL TESTING SERVICES MARKET 77
    5.7 ECOSYSTEM/MARKET MAP
           TABLE 3 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: ECOSYSTEM
    5.8 VALUE CHAIN ANALYSIS: DRUG DEVELOPMENT & MANUFACTURING PROCESS
           FIGURE 24 VALUE CHAIN ANALYSIS: DRUG DEVELOPMENT & MANUFACTURING PROCESS
    5.9 PATENT ANALYSIS: BIOANALYTICAL TESTING
           FIGURE 25 MAJOR PATENTS FOR BIOANALYTICAL TESTING
    5.10 CASE STUDY ANALYSIS
           5.10.1 CASE STUDY 1: WELLSTAT THERAPEUTICS & ALMAC GROUP
           5.10.2 CASE STUDY 2: METHOD DEVELOPMENT CASE STUDY
    5.11 TECHNOLOGICAL ANALYSIS IN HEALTHCARE ANALYTICAL TESTING SERVICES
           5.11.1 LIMS (LABORATORY INFORMATION SYSTEMS) PLATFORMS
    5.12 REGULATORY LANDSCAPE
           TABLE 4 ICH QUALITY GUIDELINES FOR PHARMACEUTICAL GMPS
           TABLE 5 DEVELOPMENT OF GLP ACROSS COUNTRIES
           TABLE 6 OVERVIEW OF GUIDELINES OF LABORATORY SERVICES
           TABLE 7 REGULATORY AUTHORITIES AND LAUNCH OF GLP MONITORING PROGRAMS IN EUROPEAN COUNTRIES
    5.13 PORTER’S FIVE FORCES ANALYSIS
           TABLE 8 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.13.1 THREAT FROM NEW ENTRANTS
                    5.13.1.1 Highly fragmented market despite ongoing consolidation
           5.13.2 BARGAINING POWER OF SUPPLIERS
                    5.13.2.1 Technical expertise of specific market players
           5.13.3 INTENSITY OF COMPETITIVE RIVALRY
                    5.13.3.1 Large number of healthcare analytical testing services companies at the regional level
           5.13.4 BARGAINING POWER OF BUYERS
                    5.13.4.1 Rising pressure on pharmaceutical companies to increase ROI, and R&D productivity
           5.13.5 THREAT FROM SUBSTITUTES
                    5.13.5.1 Rising preference by pharmaceutical companies for outsourcing drug development

6 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE (Page No. - 87)
    6.1 INTRODUCTION
           TABLE 9 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
    6.2 BIOANALYTICAL TESTING SERVICES
           TABLE 10 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 11 BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.2.1 CELL-BASED ASSAY SERVICES
                    6.2.1.1 The growing pipeline of biologics drives the growth of cell-based assays
                               TABLE 12 CELL-BASED ASSAY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.2.2 VIROLOGY TESTING SERVICES
                    6.2.2.1 Regulatory requirements drive the growth of virology testing in the drug development process
                               TABLE 13 VIROLOGY TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.2.3 IMMUNOGENICITY & NEUTRALIZING ANTIBODY TESTING SERVICES
                    6.2.3.1 The rising need to ensure the clinical safety of biopharmaceuticals drives the growth of this segment
                               TABLE 14 IMMUNOGENICITY & NEUTRALIZING ANTIBODY TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.2.4 BIOMARKER TESTING SERVICES
                    6.2.4.1 The need to improve the monitoring of drug activity and therapeutic response will drive the biomarker testing services market
                               TABLE 15 BIOMARKER TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.2.5 PHARMACOKINETIC TESTING SERVICES
                    6.2.5.1 The increasing number of clinical and preclinical studies promote the growth of this segment
                               TABLE 16 PHARMACOKINETIC TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.2.6 OTHER BIOANALYTICAL TESTING SERVICES
                    TABLE 17 OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.3 PHYSICAL CHARACTERIZATION SERVICES
           TABLE 18 PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 19 PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.3.1 LASER PARTICLE SIZE ANALYSIS SERVICES
                    6.3.1.1 The need to maintain particle size, uniformity, and consistency in pharmaceutical drug products is driving market growth
                               TABLE 20 LASER PARTICLE SIZE ANALYSIS SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.3.2 THERMAL ANALYSIS SERVICES
                    6.3.2.1 The rising usage of solid dispersions and other polymeric dosage forms will drive the growth of this market
                               TABLE 21 THERMAL ANALYSIS SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.3.3 IMAGE ANALYSIS SERVICES
                    6.3.3.1 Growing complexity of biological structures to support the growth of this market
                               TABLE 22 IMAGE ANALYSIS SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.3.4 SURFACE AREA ANALYSIS SERVICES
                    6.3.4.1 Growing application of surface analysis in streamlining the drug development process to drive the growth of the segment
                               TABLE 23 SURFACE AREA ANALYSIS SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.3.5 OTHER PHYSICAL CHARACTERIZATION SERVICES
                    TABLE 24 OTHER PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.4 METHOD DEVELOPMENT & VALIDATION SERVICES
           TABLE 25 METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 26 METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.4.1 EXTRACTABLES/LEACHABLES METHOD DEVELOPMENT & VALIDATION SERVICES
                    6.4.1.1 Extractable studies are required to facilitate the analysis of leachables and control leachables in final drug products
                               TABLE 27 EXTRACTABLES/LEACHABLES METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.4.2 PROCESS IMPURITY METHOD DEVELOPMENT & VALIDATION SERVICES
                    6.4.2.1 Regulatory requirements to control process impurities to drive the growth of this segment in the drug development process
                               TABLE 28 PROCESS IMPURITY METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.4.3 STABILITY-INDICATING METHOD VALIDATION SERVICES
                    6.4.3.1 Need to guarantee safety, efficacy, and quality of therapeutic product to drive the growth of this market
                               TABLE 29 STABILITY-INDICATING METHOD VALIDATION SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.4.4 CLEANING VALIDATION SERVICES
                    6.4.4.1 Cleaning validation processes are necessary to evaluate cleaning practices and ensure complete decontamination
                               TABLE 30 CLEANING VALIDATION SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.4.5 ANALYTICAL STANDARD CHARACTERIZATION SERVICES
                    6.4.5.1 Analytical standard characterization plays a vital role in drug development
                               TABLE 31 ANALYTICAL STANDARD CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.4.6 TECHNICAL CONSULTING SERVICES
                    6.4.6.1 Technical consulting services assist pharmaceutical and biopharmaceutical companies in meeting regulatory requirements
                               TABLE 32 TECHNICAL CONSULTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.4.7 OTHER METHOD DEVELOPMENT & VALIDATION SERVICES
                    TABLE 33 OTHER METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.5 RAW MATERIAL TESTING SERVICES
           TABLE 34 RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 35 RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.5.1 COMPLETE COMPENDIAL TESTING SERVICES
                    6.5.1.1 Complete compendial testing detects the efficacy and safety of therapeutic products
                               TABLE 36 COMPLETE COMPENDIAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.5.2 CONTAINER TESTING SERVICES
                    6.5.2.1 Container closure integrity testing helps optimize sealing, evaluate temperature impact, and replace sterility tests for product stability batches
                               TABLE 37 CONTAINER TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.5.3 HEAVY METAL TESTING SERVICES
                    6.5.3.1 Heavy metals in finished pharmaceutical products and raw materials are tested to ensure the quality of the product & patient safety
                               TABLE 38 HEAVY METAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.5.4 KARL FISCHER ANALYSIS SERVICES
                    6.5.4.1 Need to check for water content in pharmaceutical products to support the market growth
                               TABLE 39 KARL FISCHER ANALYSIS TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.5.5 WET CHEMISTRY ANALYSIS SERVICES
                    6.5.5.1 Wet chemistry analysis provides qualitative and quantitative data on elements in samples
                               TABLE 40 WET CHEMISTRY ANALYSIS TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.5.6 OTHER RAW MATERIAL TESTING SERVICES
                    TABLE 41 OTHER RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.6 BATCH-RELEASE TESTING SERVICES
           TABLE 42 BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 43 BATCH-RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.6.1 DISSOLUTION TESTING SERVICES
                    6.6.1.1 Dissolution testing plays a vital role in the pharmaceutical industry, from R&D to the control and evaluation of drug quality
                               TABLE 44 DISSOLUTION TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.6.2 ELEMENTAL IMPURITY TESTING SERVICES
                    6.6.2.1 The need to detect organic and inorganic impurities in active pharmaceuticals and ingredients drives demand for elemental impurity testing
                               TABLE 45 ELEMENTAL PURITY TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.6.3 DISINTEGRATION TESTING SERVICES
                    6.6.3.1 Disintegration testing is performed to ensure batch-to-batch consistency of pharmaceutical dosage forms
                               TABLE 46 BREAKDOWN OF DISINTEGRATION METHODS AND IMMERSION MEDIA
                               TABLE 47 DISINTEGRATION TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.6.4 HARDNESS TESTING SERVICES
                    6.6.4.1 Hardness testing helps determine resistance to mechanical shocks and tablet strength
                               TABLE 48 HARDNESS TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.6.5 FRIABILITY TESTING SERVICES
                    6.6.5.1 Friability testing measures the resistance of tablets and granules to abrasion or fracture
                               TABLE 49 FRIABILITY TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.6.6 OTHER BATCH-RELEASE TESTING SERVICES
                    TABLE 50 OTHER BATCH-RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.7 STABILITY TESTING SERVICES
           TABLE 51 STABILITY TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 52 STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.7.1 DRUG SUBSTANCE STABILITY TESTING SERVICES
                    6.7.1.1 Substance stability testing is a necessary step in the drug approval process
                               TABLE 53 DRUG SUBSTANCE STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.7.2 FORMULATION EVALUATION STABILITY TESTING SERVICES
                    6.7.2.1 These tests provide data on expiry and storage conditions required
                               TABLE 54 FORMULATION EVALUATION STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.7.3 ACCELERATED STABILITY TESTING SERVICES
                    6.7.3.1 Accelerated stability testing determines the shelf-life of a pharmaceutical product by measuring degradation caused by stress
                               TABLE 55 ACCELERATED STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.7.4 PHOTOSTABILITY TESTING SERVICES
                    6.7.4.1 Photostability tests establish the effect of light exposure on products
                               TABLE 56 PHOTOSTABILITY TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.7.5 COMPARATIVE STABILITY TESTING SERVICES
                    6.7.5.1 Comparator studies and blind comparator stability testing are performed to check if a pharmaceutical product is equivalent or superior to the marketed drug product in the same therapeutic class
                               TABLE 57 COMPARATIVE STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.7.6 OTHER STABILITY TESTING SERVICES
                    TABLE 58 OTHER STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.8 MICROBIAL TESTING SERVICES
           TABLE 59 MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 60 MICROBIAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.8.1 MICROBIAL LIMIT TESTING SERVICES
                    6.8.1.1 Microbial limit testing determines whether a product complies with compendial specifications for microbial quality
                               TABLE 61 STANDARD LIMITS FOR MICROBIAL LIMIT TESTING
                               TABLE 62 MICROBIAL LIMIT TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.8.2 STERILITY TESTING SERVICES
                    6.8.2.1 Sterility testing of a pharmaceutical product is required during the sterilization validation process and routine release testing to enhance product quality
                               TABLE 63 STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.8.3 ENDOTOXIN TESTING SERVICES
                    6.8.3.1 LAL tests are used to test for the presence of endotoxins in compliance with regulatory requirements
                               TABLE 64 ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.8.4 PRESERVATIVE EFFICACY TESTING SERVICES
                    6.8.4.1 Preservative efficacy testing determines the type and minimum effective concentration of preservatives required for a formulation
                               TABLE 65 PRESERVATIVE EFFICACY TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 143
           6.8.5 WATER TESTING SERVICES
                    6.8.5.1 Need to ensure water quality creates demand for water testing
                               TABLE 66 STANDARDIZED LIMITS FOR WATER TESTING
                               TABLE 67 WATER TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.8.6 OTHER MICROBIAL TESTING SERVICES
                    TABLE 68 OTHER MICROBIAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.9 ENVIRONMENTAL MONITORING SERVICES 146
           TABLE 69 ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 70 ENVIRONMENTAL MONITORING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.9.1 AIR TESTING SERVICES
                    6.9.1.1 Air contamination can prove highly harmful to product quality, which necessitates regular testing
                               TABLE 71 PURITY CLASSES FOR PARTICLES, WATER, AND OIL IN COMPRESSED AIR
                               TABLE 72 AIR TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.9.2 WATER TESTING SERVICES
                    6.9.2.1 Need to minimize water contamination supports the demand for water testing
                               TABLE 73 STANDARDS FOR WASTEWATER QUALITY
                               TABLE 74 WATER TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.9.3 OTHER ENVIRONMENTAL MONITORING SERVICES
                    TABLE 75 OTHER ENVIRONMENTAL MONITORING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

7 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER (Page No. - 152)
    7.1 INTRODUCTION
           TABLE 76 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
    7.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
           7.2.1 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES DOMINATE THE HEALTHCARE TESTING SERVICES MARKET
                    FIGURE 26 R&D SPENDING OF PHRMA MEMBER-COMPANIES, 1995–2019
                    TABLE 77 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
    7.3 MEDICAL DEVICE COMPANIES
           7.3.1 R&D SPENDING ON MEDICAL DEVICE DEVELOPMENT HAS INCREASED IN RECENT YEARS
                    TABLE 78 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
    7.4 CONTRACT RESEARCH ORGANIZATIONS
           7.4.1 INCREASING FOCUS ON OUTSOURCING WILL SUPPORT MARKET GROWTH
                     TABLE 79 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR CROS, BY COUNTRY, 2019–2026 (USD MILLION)

8 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY REGION (Page No. - 158)
    8.1 INTRODUCTION
           FIGURE 27 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
           TABLE 80 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
    8.2 NORTH AMERICA
           FIGURE 28 TOTAL NUMBER OF CLINICAL TRIALS: GLOBAL VS. NORTH AMERICA (2019)
           FIGURE 29 NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET SNAPSHOT
           TABLE 81 NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 82 NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 83 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 84 NORTH AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 85 NORTH AMERICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 86 NORTH AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 87 NORTH AMERICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 88 NORTH AMERICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 89 NORTH AMERICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 90 NORTH AMERICA: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 91 NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
           8.2.1 US
                    8.2.1.1 The US dominated the North American healthcare analytical testing services market in 2020
                               FIGURE 30 US: PIPELINE SPLIT OF PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY PHASE (JANUARY 2019)
                               TABLE 92 US: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 93 US: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 94 US: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 95 US: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 96 US: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 97 US: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 98 US: STABILITY TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 99 US: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 100 US: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 101 US: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
           8.2.2 CANADA
                    8.2.2.1 Increasing number of clinical trials to support the growth of the market
                               TABLE 102 NUMBER OF ACTIVE CLINICAL TRIALS IN CANADA, BY CONDITION (2020)
                               TABLE 103 CANADA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 104 CANADA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 105 CANADA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 106 CANADA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 107 CANADA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 108 CANADA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 109 CANADA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 110 CANADA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 111 CANADA: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 112 CANADA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
    8.3 EUROPE
           TABLE 113 EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 114 EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 115 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 116 EUROPE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 117 EUROPE: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 118 EUROPE: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 119 EUROPE: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 120 EUROPE: STABILITY TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 121 EUROPE: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 122 EUROPE: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 123 EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
           8.3.1 GERMANY
                    8.3.1.1 Growing biopharmaceutical sector in the country driving market growth
                               TABLE 124 GERMANY: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 125 GERMANY: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 126 GERMANY: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 127 GERMANY: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 128 GERMANY: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 129 GERMANY: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 130 GERMANY: STABILITY TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 131 GERMANY: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 132 GERMANY: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 133 GERMANY: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
           8.3.2 UK
                    8.3.2.1 Increasing partnerships between the government, the NHS, and the pharmaceutical & life sciences sector to support the market growth
                               TABLE 134 UK: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 135 UK: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 136 UK: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 137 UK: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 138 UK: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 139 UK: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 140 UK: STABILITY TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 141 UK: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 142 UK: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 143 UK: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
           8.3.3 FRANCE
                    8.3.3.1 Growing pharmaceutical R&D expenditure in the country driving market growth
                               TABLE 144 FRANCE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 145 FRANCE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 146 FRANCE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 147 FRANCE: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 148 FRANCE: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 149 FRANCE: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 150 FRANCE: STABILITY TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 151 FRANCE: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 152 FRANCE: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 153 FRANCE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
           8.3.4 ITALY
                    8.3.4.1 A growing number of clinical trials to support the market in Italy
                               TABLE 154 ITALY: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 155 ITALY: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 156 ITALY: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 157 ITALY: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 158 ITALY: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 159 ITALY: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 160 ITALY: STABILITY TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 161 ITALY: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 162 ITALY: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 163 ITALY: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
           8.3.5 SWITZERLAND
                    8.3.5.1 Large and growing pharma production volume will drive demand for analytical testing services
                               TABLE 164 SWITZERLAND: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 165 SWITZERLAND: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 166 SWITZERLAND: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 167 SWITZERLAND: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 168 SWITZERLAND: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 169 SWITZERLAND: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 170 SWITZERLAND: STABILITY TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 171 SWITZERLAND: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 172 SWITZERLAND: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 173 SWITZERLAND: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
           8.3.6 SPAIN
                    8.3.6.1 Rising R&D expenditure to boost the growth of analytical testing services
                               TABLE 174 SPAIN: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 175 SPAIN: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 176 SPAIN: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 177 SPAIN: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 178 SPAIN: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 179 SPAIN: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 180 SPAIN: STABILITY TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 181 SPAIN: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 182 SPAIN: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 183 SPAIN: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
           8.3.7 REST OF EUROPE
                    TABLE 184 ROE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 185 ROE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 186 ROE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 187 ROE: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 188 ROE: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 189 ROE: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 190 ROE: STABILITY TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 191 ROE: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 192 ROE: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 193 ROE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
    8.4 ASIA PACIFIC
           FIGURE 31 APAC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET SNAPSHOT
           TABLE 194 APAC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 195 APAC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 196 APAC: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 197 APAC: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 198 APAC: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 199 APAC: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 200 APAC: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 201 APAC: STABILITY TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 202 APAC: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 203 APAC: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 204 APAC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
           8.4.1 CHINA
                    8.4.1.1 Large pharmaceutical R&D footprint in China will drive market growth
                               TABLE 205 CHINA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 206 CHINA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 207 CHINA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 208 CHINA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 209 CHINA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 210 CHINA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 211 CHINA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 212 CHINA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 213 CHINA: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 214 CHINA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
           8.4.2 JAPAN
                    8.4.2.1 Japan is notable for demonstrating strong support for R&D
                               TABLE 215 JAPAN: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 216 JAPAN: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 217 JAPAN: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 218 JAPAN: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 219 JAPAN: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 220 JAPAN: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 221 JAPAN: STABILITY TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 222 JAPAN: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 223 JAPAN: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 224 JAPAN: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
           8.4.3 INDIA
                    8.4.3.1 India to offer lucrative growth opportunities for market players
                               TABLE 225 INCREASE IN THE R&D EXPENDITURE OF TOP FIVE INDIAN PHARMACEUTICAL COMPANIES, 2010 VS. 2018 (USD MILLION)
                               TABLE 226 INDIA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 227 INDIA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 228 INDIA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 229 INDIA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 230 INDIA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 231 INDIA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 232 INDIA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 233 INDIA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 234 INDIA: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 235 INDIA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
           8.4.4 AUSTRALIA
                    8.4.4.1 Australia is a favorable location for drug discovery due to the large number of research institutes in the country
                               TABLE 236 AUSTRALIA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 237 AUSTRALIA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 238 AUSTRALIA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 239 AUSTRALIA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 240 AUSTRALIA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 241 AUSTRALIA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 242 AUSTRALIA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 243 AUSTRALIA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 244 AUSTRALIA: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 245 AUSTRALIA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
           8.4.5 SOUTH KOREA
                    8.4.5.1 Growth in clinical trial activity to support the market in South Korea
                               TABLE 246 SOUTH KOREA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 247 SOUTH KOREA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 248 SOUTH KOREA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 249 SOUTH KOREA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 250 SOUTH KOREA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 251 SOUTH KOREA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 252 SOUTH KOREA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 253 SOUTH KOREA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 254 SOUTH KOREA: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 255 SOUTH KOREA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
           8.4.6 REST OF ASIA PACIFIC
                    TABLE 256 ROAPAC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 257 ROAPAC: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 258 ROAPAC: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 259 ROAPAC: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 260 ROAPAC: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 261 ROAPAC: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 262 ROAPAC: STABILITY TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 263 ROAPAC: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 264 ROAPAC: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 265 ROAPAC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
    8.5 LATIN AMERICA
           8.5.1 GROWING R&D EXPENDITURE TO DRIVE MARKET GROWTH
                    TABLE 266 LATIN AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 267 LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 268 LATIN AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 269 LATIN AMERICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 270 LATIN AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 271 LATIN AMERICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 272 LATIN AMERICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 273 LATIN AMERICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 274 LATIN AMERICA: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 275 LATIN AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
    8.6 MIDDLE EAST & AFRICA
           8.6.1 MIDDLE EASTERN COUNTRIES ARE BECOMING ATTRACTIVE DESTINATIONS FOR PHARMA & MEDICAL DEVICE MANUFACTURERS
                    TABLE 276 MIDDLE EAST & AFRICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 277 MIDDLE EAST & AFRICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 278 MIDDLE EAST & AFRICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 279 MIDDLE EAST & AFRICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 280 MIDDLE EAST & AFRICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 281 MIDDLE EAST & AFRICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 282 MIDDLE EAST & AFRICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 283 MIDDLE EAST & AFRICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 284 MIDDLE EAST & AFRICA: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 285 MIDDLE EAST & AFRICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)

9 COMPETITIVE LANDSCAPE (Page No. - 264)
    9.1 INTRODUCTION
    9.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
           9.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE HEALTHCARE ANALYTICAL TESTING SERVICES MARKET
    9.3 REVENUE SHARE ANALYSIS
           9.3.1 REVENUE ANALYSIS FOR KEY PLAYERS IN THE HEALTHCARE ANALYTICAL TESTING SERVICES MARKET
                    FIGURE 32 REVENUE ANALYSIS FOR KEY PLAYERS IN THE HEALTHCARE ANALYTICAL TESTING SERVICES MARKET IN THE PAST FIVE YEARS
    9.4 MARKET SHARE ANALYSIS
           9.4.1 MARKET SHARE ANALYSIS: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET
                    FIGURE 33 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET SHARE, BY KEY PLAYER, 2020
                    TABLE 286 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: DEGREE OF COMPETITION
    9.5 COMPANY EVALUATION QUADRANT
           9.5.1 COMPANY EVALUATION QUADRANT: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET
                    9.5.1.1 Stars
                    9.5.1.2 Pervasive players
                    9.5.1.3 Emerging leaders
                    9.5.1.4 Participants
                               FIGURE 34 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET (GLOBAL) COMPETITIVE LEADERSHIP MAPPING, 2020
    9.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS (2020)
           9.6.1 PROGRESSIVE COMPANIES
           9.6.2 DYNAMIC COMPANIES
           9.6.3 STARTING BLOCKS
           9.6.4 RESPONSIVE COMPANIES
                    FIGURE 35 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: SME/START-UP COMPANY EVALUATION MATRIX, 2020
    9.7 COMPETITIVE BENCHMARKING
           9.7.1 COMPANY SERVICE FOOTPRINT (20 COMPANIES)
                    FIGURE 36 COMPANY SERVICE FOOTPRINT (20 COMPANIES)
                    TABLE 287 COMPANY END-USER FOOTPRINT (20 COMPANIES)
                    TABLE 288 COMPANY REGION FOOTPRINT (20 COMPANIES)
                    FIGURE 37 GEOGRAPHICAL ASSESSMENT OF THE KEY PLAYERS IN THE HEALTHCARE ANALYTICAL TESTING SERVICES MARKET (2020)
    9.8 COMPETITIVE SITUATIONS AND TRENDS
           9.8.1 SERVICE LAUNCHES & APPROVALS
                    TABLE 289 SERVICE LAUNCHES (2018–AUGUST 2021)
           9.8.2 DEALS
                    TABLE 290 DEALS (2018–AUGUST 2021)
                    TABLE 291 OTHER DEVELOPMENTS (2018–AUGUST 2021)

10 COMPANY PROFILES (Page No. - 280)
     10.1 KEY PLAYERS
(Business Overview, Products/Solutions Offered, Recent Developments, Winning Imperatives, Current Focus and Strategies, Threat From Competition, Right to Win)* 
             10.1.1 EUROFINS SCIENTIFIC
                        TABLE 292 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW
                        FIGURE 38 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2020)
             10.1.2 LABORATORY CORPORATION OF AMERICA HOLDINGS
                         TABLE 293 LABCORP: BUSINESS OVERVIEW
                        FIGURE 39 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2020)
             10.1.3 SGS
                         TABLE 294 SGS S.A.: BUSINESS OVERVIEW
                        FIGURE 40 SGS: COMPANY SNAPSHOT (2020)
             10.1.4 CHARLES RIVER LABORATORIES
                         TABLE 295 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW
                        FIGURE 41 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2020)
             10.1.5 WUXI APPTEC
                         TABLE 296 WUXI APPTEC CO. LTD: BUSINESS OVERVIEW
                        FIGURE 42 WUXI APPTEC: COMPANY SNAPSHOT (2020)
             10.1.6 PPD
                         TABLE 297 PPD: BUSINESS OVERVIEW
                        FIGURE 43 PPD: COMPANY SNAPSHOT (2020)
             10.1.7 ELEMENT MATERIALS TECHNOLOGY
                         TABLE 298 ELEMENT MATERIALS TECHNOLOGY: BUSINESS OVERVIEW
             10.1.8 THERMO FISHER SCIENTIFIC
                         TABLE 299 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
                        FIGURE 44 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT: (2020)
             10.1.9 PACE ANALYTICAL SERVICES
                         TABLE 300 PACE ANALYTICAL SERVICES: BUSINESS OVERVIEW
             10.1.10 INTERTEK GROUP
                         TABLE 301 INTERTEK GROUP PLC: BUSINESS OVERVIEW
                        FIGURE 45 INTERTEK: COMPANY SNAPSHOT (2020)
             10.1.11 MERCK KGAA
                         TABLE 302 MERCK KGAA: BUSINESS OVERVIEW
                        FIGURE 46 MERCK: COMPANY SNAPSHOT (2020)
             10.1.12 DANAHER CORPORATION
                         TABLE 303 DANAHER CORPORATION: BUSINESS OVERVIEW
                        FIGURE 47 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)
             10.1.13 SOURCE BIOSCIENCE
                         TABLE 304 SOURCE BIOSCIENCE: BUSINESS OVERVIEW
             10.1.14 ALMAC GROUP
                         TABLE 305 ALMAC GROUP: BUSINESS OVERVIEW
             10.1.15 ICON
                         TABLE 306 ICON: BUSINESS OVERVIEW
                        FIGURE 48 ICON: COMPANY SNAPSHOT (2020)
             10.1.16 ALS LIFE SCIENCES
                         TABLE 307 ALS LIFE SCIENCES: BUSINESS OVERVIEW
                        FIGURE 49 ALS LIFE SCIENCES: COMPANY SNAPSHOT (2020)
             10.1.17 FRONTAGE LABORATORIES
                         TABLE 308 FRONTAGE LABORATORIES: BUSINESS OVERVIEW
                        FIGURE 50 FRONTAGE LABORATORIES: COMPANY SNAPSHOT (2020)
             10.1.18 STERIS
                         TABLE 309 STERIS: BUSINESS OVERVIEW
                        FIGURE 51 STERIS: COMPANY SNAPSHOT (2021)
             10.1.19 SARTORIUS AG
                         TABLE 310 SARTORIUS AG: BUSINESS OVERVIEW
                        FIGURE 52 SARTORIUS: COMPANY SNAPSHOT (2020)
     10.2 OTHER EMERGING PLAYERS
             10.2.1 SYNEOS HEALTH
                         TABLE 311 SYNEOS HEALTH: BUSINESS OVERVIEW
             10.2.2 MEDPACE HOLDINGS
                         TABLE 312 MEDPACE HOLDINGS: BUSINESS OVERVIEW
             10.2.3 LGC LIMITED (CINVEN)
                         TABLE 313 LGC LIMITED: BUSINESS OVERVIEW
             10.2.4 ANACURA
                         TABLE 314 ANACURA: BUSINESS OVERVIEW
             10.2.5 IMPACT ANALYTICAL
             10.2.6 CD BIOSCIENCES
*Business Overview, Products/Solutions Offered, Recent Developments, Winning Imperatives, Current Focus and Strategies, Threat From Competition, Right to Win might not be captured in case of unlisted companies. 

11 APPENDIX (Page No. - 348)
     11.1 DISCUSSION GUIDE
     11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     11.3 AVAILABLE CUSTOMIZATIONS
     11.4 RELATED REPORTS
     11.5 AUTHOR DETAILS

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

Secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Business, Factiva, and D&B Hoovers), white papers, annual reports, companies house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the healthcare analytical testing services market. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The healthcare analytical testing services market comprises several stakeholders such as healthcare analytical testing service providers including bioanalytical testing services providers and environmental testing providers. The demand side of this market includes pharmaceutical & biopharmaceutical companies, medical device companies, and contract research organizations (CROs).

Various primary sources from both, the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.

Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends & key market dynamics.

A breakdown of the primary respondents for the healthcare analytical testing services market is provided below:

Healthcare Analytical Testing Services Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (segmental analysis of major segments) and top-down approach (assessment of utilization/adoption/penetration trends, by type, by end user and by region.

Data Triangulation

After arriving at the market size, the total healthcare analytical testing services market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments & subsegments, data triangulation, and market breakdown procedures were employed, wherever applicable.

Objectives of the Study

  • To define, describe, analyze, and forecast the size of the healthcare analytical testing services market on the basis of type, end-user, and region.
  • To provide detailed information on the major factors influencing market growth (drivers, restraints, opportunities, and industry-specific challenges)
  • To strategically analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall market
  • To forecast the size of the market segments with respect to North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
  • To profile key players and comprehensively analyze their service portfolios, market positions, and core competencies.
  • To track and analyze competitive developments such as service launches, expansions, partnerships, agreements, collaborations, acquisitions and other developments in the market.
  • To benchmark players within the healthcare analytical testing services market using the Competitive Leadership Mapping framework which analyzes market players on various parameters within the broad categories of business and service strategy.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players

Geographic Analysis

  • Further breakdown of the RoAPAC healthcare analytical testing services market into New Zealand and other countries
  • Further breakdown of the RoE healthcare analytical testing services market into Belgium, Russia, the Netherlands, and other countries
  • Further breakdown of Latin America healthcare analytical testing services market into Brazil, Mexico, and other countries.
COVID-19

Get in-depth analysis of the COVID-19 impact on the Healthcare Analytical Testing Services Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Healthcare Analytical Testing Services Market

Request For Special Pricing
Report Code
AST 4341
Published ON
Sep, 2021
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Healthcare Analytical Testing Services Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved